| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7390115 | Value in Health Regional Issues | 2016 | 7 Pages |
Abstract
Although tocilizumab and methotrexate provide a larger gain in quality-adjusted life-years, their current price is quite high as compared with those of our other interventions. Therefore, a regimen containing tocilizumab is not cost-effective as compared with an infliximab-containing regimen for patients with rheumatoid arthritis in Iran.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Amir PharmD, Shekoufeh PharmD, PhD, Elizabeth MS, MA, Ahmadreza MD, Seyed Alireza PharmD, PhD,